Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.94 USD | +3.16% | -9.54% | +26.72% |
20/03 | North American Morning Briefing : Markets on Hold -2- | DJ |
19/03 | JPMorgan Upgrades Mersana Therapeutics to Neutral From Underweight, Price Target is $5 | MT |
Sales 2024 * | 39.05M 3.26B | Sales 2025 * | 33.24M 2.77B | Capitalization | 360M 30.01B |
---|---|---|---|---|---|
Net income 2024 * | -83M -6.92B | Net income 2025 * | -97M -8.09B | EV / Sales 2024 * | 6.39 x |
Net cash position 2024 * | 110M 9.19B | Net cash position 2025 * | 23.7M 1.98B | EV / Sales 2025 * | 10.1 x |
P/E ratio 2024 * |
-4.43
x | P/E ratio 2025 * |
-4.07
x | Employees | 123 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.32% |
Latest transcript on Mersana Therapeutics, Inc.
1 day | +3.16% | ||
1 week | -9.54% | ||
Current month | -34.38% | ||
1 month | -34.38% | ||
3 months | -8.70% | ||
6 months | +153.45% | ||
Current year | +26.72% |
Managers | Title | Age | Since |
---|---|---|---|
Martin Huber
CEO | Chief Executive Officer | 64 | 13/20/13 |
Director of Finance/CFO | 46 | 10/19/10 | |
David Mott
CHM | Chairman | 58 | 31/12/31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kristen Hege
BRD | Director/Board Member | 60 | 01/16/01 |
David Mott
CHM | Chairman | 58 | 31/12/31 |
Anna Protopapas
BRD | Director/Board Member | 59 | 02/15/02 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.05% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - | |
0.03% | 237 M€ | +2.89% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 2.94 | +3.16% | 858,610 |
25/24/25 | 2.85 | -1.04% | 1,996,373 |
24/24/24 | 2.88 | -10.28% | 3,535,445 |
23/24/23 | 3.21 | +1.90% | 1,880,124 |
22/24/22 | 3.15 | -3.08% | 1,803,183 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.72% | 360M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+0.52% | 22.15B | |
-17.37% | 21.02B | |
-8.98% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- MRSN Stock